Neostigmine Hyperinflation

Astava A Hunter JM , Reversal of neuromuscular block. Br J Anaesth. 2009;103(1):115–129.

McLean DJ Diaz-Gil D Farhan HN . Dose-dependent association between intermediate-acting neuromuscular-blocking agents and postoperative respiratory complications. Anesthesiology. 2015;122(6):1201–1213.

Eclat Pharmaceuticals. Bloxiverz® [package insert]. Chesterfield, MO: Eclat Pharmaceuticals; 2013.

Sasaki N Meyer M Malviya A . Effects of neostigmine reversal of nondepolarizing neuromuscular blocking agents on postoperative respiratory outcomes. Anesthesiology. 2014;121(5):959–968.

Mantegazza R Bonanno S Camera G . Current and emerging therapies for the treatment of myasthenia gravis. Neuropsychiatr Dis Treat. 2011;7:151–160.

US Food and Drug Administration, Center for Drug Evaluation and Research. Neostigmine NDA Clinical Review 204078. 2013. https://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/DevelopmentResources/UCM361414.pdf. Accessed May 15, 2017.

FDA Issues Revised Guidance on Marketed Unapproved Drugs . 2014. http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/EnforcementActivitiesbyFDA/SelectedEnforcementActionsonUnapprovedDrugs/ucm270831.htm. Accessed February 3, 2017.

Greenberg S . The neostigmine shortage: a clinical conundrum with few drug alternatives. The Official Journal of the Anesthesia Patient Safety Foundation—APSF Newsletter. 2015. http://www.apsf.org/newsletters/html/2015/Oct/04_Neostigmine.htm. Accessed January 31, 2017.

Flamel Technologies Announces Acquisition of Éclat Pharmaceuticals. 2014. http://www.businesswire.com/news/home/20120314006675/en/Flamel-Technologies-Announces-Acquisition-%C3%89clat-Pharmaceuticals. Accessed April 10, 2017.

Flamel Technologies Completes Cross-Border Merger with Avadel Pharmaceuticals (AVDL) Becoming Surviving Public Company. 2017. https://www.streetinsider.com/Corporate+News/Flamel+Technologies+Completes+Cross-Border+Merger+with+Avadel+Pharmaceuticals+(AVDL)+Becoming+Surviving+Public+Company/12383533.html. Accessed April 10, 2017.

Flamel Technologies Announces FDA Approval of Bloxiverz. 2013. http://www.marketwired.com/press-release/flamel-technologies-announces-fda-approval-of-bloxiverz-nasdaq-flml-1797175.htm. Accessed February 28, 2017.

Ronny H. Flamel Technologies: Bloxiverz Competition to Cease Marketing. 2014. http://seekingalpha.com/article/2306535-flamel-technologies-bloxiverz-competition-to-cease-marketing. Accessed February 28, 2017.

NORC at the University of Chicago. Final Report: Trends in Hospital Inpatient Drug Costs: Issues and Challenges. Presented to American Hospital Association. Chicago, IL: NORC at the University of Chicago; 2016.

Langreth R . 2,000% Drug Price Surge Is a Side Effect of FDA Safety Program. 2015. www.bloomberg.com/news/articles/2015-10-06/2-000-drug-price-surge-is-a-side-effect-of-fda-safety-program.

Wheeler M . Current Drug Shortages - Neostigmine Methylsulfate Injection. 2015. American Society of Health-System Pharmacists http://www.ashp.org/menu/DrugShortages/ResolvedShortages/Bulletin.aspx?id=1150. Accessed May 15, 2017.

Rubenfire A . Drug price hikes may be hitting hospitals harder than consumers. 2016. http://www.modernhealthcare.com/article/20161011/NEWS/161019988. Accessed February 28, 2017.

Kounang N . Why pharmaceuticals are cheaper abroad. 2015. http://www.cnn.com/2015/08/28health/us-pays-more-for-drugs/. Accessed March 1, 2017.

Sandoz Inc. Regonol® [package insert]. Princeton, NJ: Sandoz Inc; 2009.

Bevan D Donati F Kopman AF . Reversal of neuromuscular blockade. Anesthesiology. 1992;77(4):785–805.

Mylan Institutional Inc. Enlon® [package insert]. Rockford, IL: Mylan Institutional Inc; 2013.

Mirakhur R Gibson F Lavery G . Antagonism of vecuronium induced neuromuscular blockage with edrophonium or neostigmine. Br J Anaesth. 1987;59:473–477.

DRUGDEX® system (electronic version). Greenwood Village, Colorado: Truven Health Analytics. http://www.micromedexsolutions.com/. 2017.

AmerisourceBergen Corporation Customer Ordering Portal. 2017. https://passport.amerisourcebergen.com/irj/portal/Bridion/Pricing. Accessed May 15, 2017.

Merck & Co. Inc. Bridion® [package insert]. Whitehouse Station, NJ: Merck & Co; 2016.

Kovac A . Sugammadex: a selective relaxant binding agent for neuromuscular block reversal. Formulary. 2009;44:13–21.

Pharmaceutical Compounding—sterile preparations (General Chapter <797>). In: The United States Pharmacopeia, 39th Review, and the National Formulary. 34th ed. Rockville, MD: The United States Pharmacopeial Convention; 2016:626–670.

Karen B . In operating room, a switch to prefilled syringes pays off. Anesthesiology News. 2013. http://www.anesthesiologynews.com/PRN-/Article/03-13/In-Operating-Room-A-Switch-to-Prefilled-Syringes-Pays-Off/22707/ses=ogst. Accessed January 26, 2017.